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Abstract  
The clinical efficacy of autologous vein wrapping for recurrent compressive 
neuropathy has been demonstrated; however, the underlying mechanisms of this 
technique remain unclear. Rats were divided into chronic constriction injury (CCI) and 
CCI + vein wrapping (CCI+VW) groups. Mechanical allodynia was evaluated using 
von Frey filaments. To identify the neuroprotective factors released from veins, basic 
fibroblast growth factor (bFGF) mRNA expression in veins was compared to that in the 
sciatic nerve. The response of heme oxygenase-1 (HO-1) expression to vein wrapping 
was evaluated by RT-PCR and enzyme-linked immunosorbent assays. The effects of 
exogenous bFGF on HO-1 expression were evaluated using a sciatic nerve cell culture. 
Vein wrapping significantly increased the withdraw threshold levels compared to the 
untreated CCI group. bFGF mRNA expression in veins was higher than that in untreated 
sciatic nerves. HO-1 mRNA expression was induced at higher levels in sciatic nerve 
cells in the presence of exogenous bFGF compared to untreated control cells. HO-1 
mRNA and protein expression in the sciatic nerve were also higher in the CCI+VW 
group compared with the CCI group. Our results suggest that vein-derived bFGF 
contributes to the therapeutic benefit of vein wrapping through the induction of HO-1 in 
the sciatic nerve. Vein wrapping is a useful technique for reducing neuropathic pain. 
Further understanding of the neurotrophic factors released from veins may help to 
optimize current procedures for treating recurrent compressive neuropathy and 
traumatic peripheral nerve injury, and lead to the development of new therapeutic 
methods using recombinant neurotrophic factors. 
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Introduction 
Protecting and isolating nerves from the surrounding tissues during peripheral nerve 
surgery can improve outcomes by reducing fibrosis and decreasing adhesion to 
surrounding scar tissue.1 The technique of using autologous veins as a protective 
material is called “vein wrapping”. Masear et al.2 first reported the successful use of 
vein wrapping for reducing recurrent symptoms secondary to nerve scarring. Several 
basic and clinical studies have shown that in patients with recurrent compressive 
neuropathy, such as carpal tunnel, cubital tunnel, radial tunnel, and tarsal tunnel 
syndromes, and traumatic peripheral nerve injury, vein wrapping improves nerve 
function and the symptoms associated with these disorders.3-10 However, despite the 
therapeutic potential of autologous vein wrapping, the underlying mechanisms of this 
technique have not been resolved. 
During the early phase of peripheral nerve injury, the heparin-binding protein basic 
fibroblast growth factor (bFGF) has neuroprotective effects and contributes to the 
proliferation of undifferentiated Schwann cells and nerve regeneration.11-16 Venous 
endothelial and smooth muscle cells contain large quantities of bFGF.17-19 In 
venous-venous bypass grafts, the release of bFGF from veins inserted into the arterial 
circulation is markedly increased.20 Based on these findings, we speculated that vein 
wrapping exerts neuroprotective effects through the elevated release of bFGF. 
Several in-vitro and in-vivo studies have demonstrated that anti-oxidants relieve 
neuropathic pain resulting from peripheral nerve injury.21-23 For example, heme 
oxygenase-1 (HO-1) is a rate-limiting enzyme that catalyzes the oxidative degeneration 
of heme into biliverdin, carbon monoxide, and iron. HO-1 over-expression or induction 
is associated with potent anti-inflammatory and antinociceptive effects, both in vitro and 
in mice 24-27, and also alleviates neuropathic pain induced by sciatic nerve 
injury.21,25,28-30 A recent study reported that bFGF induces HO-1 expression in spinal 
cord astrocytes in vitro.31 We therefore hypothesized that the release of bFGF by veins 
contributes to neuroprotection via the induction of HO-1 in injured sciatic nerves. 
Here, we investigated the regulation of HO-1 by bFGF in the sciatic nerve after vein 
wrapping using a rat chronic constriction injury (CCI) model. 
  
Methods 
 
Sciatic Nerve Injury Model  
All protocols for animal procedures were approved by the ethics committees of Chiba 
University and followed the National Institutes of Health Guidelines for the Care and 
Use of Laboratory Animals (1996 Revision). Eight-week-old male Wistar rats (n=140) 
weighing 240 to 260 g were used in this study. The rats were housed in a semi-barrier 
system with a controlled environment (lighting, 12-h light/dark cycle; temperature, 21- 
23 °C; humidity, 45%-65%) throughout the study. All rats were fed a diet of standard 
rodent chow (CRF-1; Oriental Yeast Co., Ltd., Tokyo, Japan). 
We generated a sciatic nerve injury model by CCI of the sciatic nerve, as described by 
Bennett and Xie.32 Briefly, rats were anesthetized with a combination of ketamine 
hydrochloride (100 mg/kg) and xylazine hydrochloride (10 mg/kg). The biceps femoris 
and gluteus superficial muscles were separated, and the right sciatic nerve was exposed. 
CCI was produced by loosely tying 4 ligations around the sciatic nerve at 1-mm 
intervals under a microscope. The ligatures were tightened until a brief twitch was 
elicited in the respective hind limb. 33 The vein graft harvested from one donor rat was 
used for the vein wrapping procedures of three rats.  
Rats were randomly divided into three groups. In the sham group (n=39), rats 
underwent exposure and decompression for suturing around the right sciatic nerve only. 
In the CCI group (n=42), rats underwent surgery to produce CCI. In the vein-wrapping 
group (n=42), rats underwent the vein wrapping procedure after CCI surgery (CCI + 
VW group). Vein grafts were harvested from the abdominal portion of the vena cava of 
donor rats 34 and were then used to wrap the ligated sciatic nerve, with the endothelial 
surface adjacent to the epineurium of the nerve, as described by Masear et al. 2 
 
Behavioral Tests   
Six rats from each experimental group were exclusively used for behavioral testing. 
The rats were randomized and acclimated to the test chamber for 1 h before performing 
the behavioral tests. Baseline thresholds were obtained 3 days before surgery. The 
behavioral testing was performed at 1, 3, 5, 7 and 14 days after surgery. 
Mechanical allodynia was assessed by probing the hind paw with non-noxious graded 
stimuli (Mono-filament Kit; Smith & Nephew, Germantown, Wisconsin) applied 
perpendicularly to the plantar surface of the paw through wire-mesh observation cages. 
The paw withdrawal threshold was determined by sequentially increasing and 
decreasing the stimulus strength, and withdrawal data was then analyzed using the 
Dixon nonparametric test 35, as described by Chaplan et al.36 
 
bFGF and HO-1mRNA Expression Analysis  
Five untreated rats were exclusively used for the analysis of bFGF mRNA expression 
in sciatic nerves and veins. After the rats were anesthetized as described above, the 
sciatic nerve and vena cava were immediately removed. 
For the analysis of HO-1 mRNA expression in the sciatic nerve, five rats in each 
experimental group were anesthetized and the ligated right sciatic nerve was resected 
before (untreated rats), and 1, 3, 5, 7, and 14 days after surgery. The resected nerves 
were separated from scar tissue, vein grafts, and ligatures. 
Total RNA was extracted from the sciatic nerve and vein samples using Trizol reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. First-strand cDNA 
synthesis was performed using Superscript III (Invitrogen) with total RNA as the 
template. Quantitative RT-PCR was then conducted with the obtained cDNA using 
gene-specific rat primers (Table 1). bFGF and HO-1 primers were designed using 
Primer Blast software (National Center for Biotechnology Information, Bethesda, MD). 
Melt curve analysis was performed to confirm the specificity of the amplified products. 
Other primers were designed based on primer sequences reported in the literature. All 
primers were purchased from Hokkaido System Science Co., Ltd. (Sapporo, Japan). The 
PCR reaction mixture consisted of 2 μL cDNA, the specific primer set (0.2 μM final 
concentration), and 12.5 μL SYBR Premix Ex Taq (Takara, Kyoto, Japan) in a final 
volume of 25 μL. Quantitative PCR was performed using a Real-Time PCR Detection 
System (CFX-96; Bio-Rad, CA). The PCR cycle parameters consisted of an initial 
denaturation step at 95 °C for 1 min, followed by 40 cycles of 95 °C for 5 s, and 60 °C 
for 30 s. mRNA expression was normalized to the level of glyceraldehyde 
dehydrogenase (GAPDH) mRNA. HO-1 mRNA expression levels were compared with 
untreated rat (treated rats/untreated rats). 
 
Enzyme-Linked Immunosorbent Assay (ELISA)  
To examine HO-1 protein expression in the sciatic nerve, eight rats from each 
experimental group were used for analysis, which was performed five days after surgery. 
For the expression analysis, resected nerves were removed and separated from scar 
tissue, vein grafts, and ligatures, and were then immediately frozen in liquid nitrogen, 
followed by homogenization in CelLytic MT Lysis buffer (Sigma, St. Louis, MO) 
supplemented with protease inhibitor cocktail (Roche, Basel, Switzerland). HO-1 
concentration in the sciatic nerve was measured using an HO-1 ELISA kit (Enzo Life 
Science, Switzerland). The total amount of protein in the collected nerve samples was 
measured using a BCA kit (Thermo Fisher Scientific Inc., Rockford, IL, USA), and 
HO-1 levels were normalized to the total amount of protein.  
 
Cell isolation from non-treated rat sciatic nerve   
Four untreated rats were anesthetized, and bilateral sciatic nerve fragments with a 
length of approximately 30 mm were collected. The sciatic nerves were washed with 25 
mL culture medium, which consisted of Dulbecco’s Modified Essential Medium 
(DMEM)/F-12 supplemented with 10% fetal calf serum and penicillin-streptomycin, 
and the epineurium was then removed using fine forceps. Nerves were cut into 1-mm 
pieces and resuspended in an enzyme mixture consisting of 250 U/mL type I-S 
hyaluronidase (Sigma) and 160 U/mL type 1 collagenase. After 18 h of incubation at 
37 °C, the nerve tissue pieces were gently triturated using a 10-mL glass pipette until 
the pieces could be readily drawn into a syringe. The trituration was repeated using a 
22-gauge needle, followed by a 27-gauge needle. The resulting suspension was 
centrifuged at 300 × g for 5 min. After resuspension in 10 mL culture medium, the 
sample was again triturated using a 27-gauge needle. The resulting cell suspension was 
washed twice in 10 mL culture medium, with centrifuging of the sample at 300 × g for 5 
min being performed after each wash. Finally, the washed cells were plated at a 
sub-confluent concentration in culture medium on poly-L-ornithine/laminin-coated six 
well plates (BD Biosciences), which were then incubated at 37 °C, 5% CO2 and > 95% 
humidity for 24 h.37 
 
Effect of bFGF on HO-1 expression of sciatic nerve cells 
Cells isolated from rat sciatic nerves, as described above, were cultured in 
poly-L-ornithine/laminin-coated six-well plates. After a 1-week incubation at 37 °C in a 
5% CO2 incubator, cells were incubated with 0 (control group) or 0.1 or 1 ng/ml human 
recombinant bFGF (Kaken Pharmaceutical Co., Ltd., Tokyo, Japan) for 2 h. The treated 
and control cells were harvested for total RNA isolation and HO-1 expression analysis 
by RT-PCR. 
 
Immunohistochemistry  
To investigate the localization of bFGF in veins and the sciatic nerve and the 
expression site of HO-1 in the sciatic nerve, immunohistochemistry was performed. At 
5 days after surgery, three untreated rats were used for bFGF localization and three rats 
from the CCI and CCI+VW groups were used for HO-1 localization. The 
paraformaldehyde-fixed vein and sciatic nerve tissues samples were embedded in 
paraffin and sliced into 4-μm thick sections. The sciatic nerve sections were cut at the 
center to avoid the ligatures. The sections were immunohistochemically stained with 
rabbit polyclonal primary antibody against bFGF (1:3000; Santa Cruz Biotechnology, 
Dallas, TX, USA), mouse monoclonal antibody against HO-1 (1:250; Abcam, 
Cambridge, UK), and rabbit polyclonal antibody against S-100 protein (1:2500; 
Leica-Novocastra, Newcastle upon Tyne, UK) using peroxidase-based staining with 
3,3'-diaminobezidine (DAB) to give a brown reaction product. Counter staining was 
performed with hematoxylin. 
The sections were examined by using a light microscope. Areas stained with S-100 
protein were recognized as the nerve bundle. The cross-sectional area of the nerve 
bundle were calculated using WinROOF Ver.7.2 (Mitani Shoji, Fukui, Japan) and 
HO-1-immunoreactive (IR) cells in the nerve bundle were counted at 400X 
magnification using counter grid. The number of HO-1 IR cells per 1 mm2 area were 
calculated and compared with the CCI and CCI+VW groups. 
 
Statistical Analyses 
All statistical analyses were performed using SPSS software (version 19.0; SPSS Inc., 
Chicago, IL). The Mann-Whitney U test was used to examine differences in bFGF 
mRNA expression between the sciatic nerves and veins. Tukey’s multiple comparison 
tests were used to examine differences among the sham, CCI and CCI+VW groups. The 
Mann-Whitney U test was also used to examine differences between the CCI and CCI + 
VW groups in histological analysis. A p value of < 0.05 was considered statistically 
significant. 
 
Results 
Behavioral tests 
In the von Frey test, rats in the CCI group displayed significant mechanical allodynia 1 
day after surgery compared with the sham group (p<0.05). Allodynia persisted for up to 
14 days after surgery. The withdraw threshold level in the CCI + VW group was 
significantly increased compared to that in the CCI group from days 3 to 5 after surgery 
(p<0.05; Figure 1).  
 
bFGF mRNA expression and localization in veins  
The endothelial surface of veins, in which cells are sparse, is relocated adjacent to the 
epineurium of the nerve by the vein wrapping procedure. To investigate the localization 
of bFGF expression in vein, immunohistochemical analyses were performed. 
Immunohistochemistry analysis revealed that bFGF-positive cells in veins mainly 
existed in the tunica media and tunica adventitia. Cells were sparsely stained within a 
small region of the tunica intima (Figure 2A). bFGF-positive cells also present in the 
sciatic nerve were sparsely stained (Figure 2B). However, bFGF mRNA expression in 
veins was five-fold higher than that in the sciatic nerve (p<0.05; Figure 2C). 
 
Effect of bFGF on expression of HO-1 in sciatic nerve cell culture 
As bFGF stimulates HO-1 expression in spinal astrocytes 31, real-time PCR was used 
to examine the regulation of HO-1 by bFGF in sciatic nerve cells (Figure 3). Expression 
of the HO-1 gene increased two fold in sciatic nerve cells in the presence of 
exogenously added bFGF (1 ng/ml) compared to untreated control cells (p<0.05). 
 
Expression and localization of HO-1 in sciatic nerves  
To investigate the possible increase of HO-1 induced by vein wrapping in vivo, HO-1 
mRNA and protein expression were examined after CCI injury with or without vein 
wrapping. Quantitative RT-PCR conducted on sciatic nerves from the CCI and 
CCI+VW groups showed that HO-1 mRNA was significantly increased compared to the 
sham group 1 to 14 days after surgery (p<0.05; Figure 4). Notably, the application of 
vein wrapping after CCI resulted in a further and significant elevation of HO-1 mRNA 
expression compared to the CCI group at 3 and 5 days after surgery (p<0.05). The 
increase in HO-1 mRNA expression induced by vein wrapping was most significant on 
day 5 after surgery (p<0.01; Figure 4).  
Based on the HO-1 mRNA expression results, HO-1 protein expression in the sciatic 
nerve was analyzed at day 5. Compared to the sham group, HO-1 protein levels were 
significantly higher in the CCI and CCI+VW groups (p<0.05). HO-1 protein levels in 
the CCI+VW group were significantly increased compared with that in the CCI group 
(p<0.05; Figure 5).  
The S100 protein-positive region was regarded as the region of a nerve bundle (Figure 
6 A,D). The cross-sectional areas of nerve bundles did not differ between the CCI and 
CCI + VW groups (CCI, 411,627 ± 45,617 um2; CCI + VW, 398,029±59,160 um2, 
P=0.827) There were virtually no HO-1 IR cells in the CCI group (Figure 6B,C). In 
contrast, HO-1 IR cells were observed in nerve bundles in the CCI+VW group (19.7 ± 
5.5 cells/mm2, Figure 6E,F). 
 
Discussion 
In this study investigating the mechanisms underlying the positive therapeutic effects 
of vein wrapping for recurrent compressive neuropathy and traumatic peripheral nerve 
injury, RT-PCR revealed that bFGF was expressed at significantly higher levels in veins 
compared to the sciatic nerve. In addition, exogenous bFGF induced HO-1 expression 
in sciatic nerve cells. Consistent with the real-time PCR and ELISA results, 
immunohistochemistry analysis showed that the application of vein wrapping increased 
HO-1 in sciatic nerve fiber bundles. Taken together, these findings suggest that bFGF 
from veins is one of the biological mechanisms that contributes to the therapeutic 
benefit of vein wrapping through the induction of HO-1 expression in the sciatic nerve. 
Several clinical studies have demonstrated promising results, including the reduction 
of allodynia, using the vein wrapping technique for the treatment of recurrent 
compressive neuropathy and traumatic peripheral nerve injury.3-10 Previous experiments 
by our group in a rat model revealed that vein wrapping after CCI decreased 
pain-associated behavior and nerve damage. 34 Here, vein wrapping also inhibited the 
development of allodynia following CCI. To determine the mechanism underlying the 
therapeutic benefit of peripheral vein wrapping, Chou et al. 38 performed 
histopathologic analysis of biopsy specimens harvested from a carpal tunnel syndrome 
patient who underwent vein wrapping and provided evidence that local factors 
originating from the vein graft directly restored or optimized the function of the injured 
nerve; however, the local factors were not identified. Here, bFGF-positive cells were 
observed in the endothelial surface and bFGF mRNA expression in veins was five-fold 
higher than that in the sciatic nerve. Several recent studies demonstrated that the 
application of exogenous bFGF with a carrier-mediated controlled release system 
facilitated nerve regeneration in transected rat sciatic nerves. 13,14,16 For example, 
Fujimoto et al. 14 used electron microscopy to examine the in-vivo bFGF treatment of rat 
sciatic nerves and found that regenerating axons grew 1.5-2-fold faster when nerve 
stumps were treated with bFGF compared with phosphate-buffered saline. In a previous 
study, we revealed that the application of vein wrapping after CCI promoted axon 
growth, myelination, nerve arrangement, and Schwann cell nucleation, and less nerve 
degeneration compared to CCI alone. 34 Based on these findings, the release of 
vein-derived bFGF at graft sites may play be important for the therapeutic effect of vein 
wrapping. 
HO-1 expressed at sites of rat sciatic nerve injury in the peripheral nervous system 
may contribute to cellular adaptive function when cells have lost contact with axons, 
and appears to play a crucial role in nerve regeneration.39 Upregulation of HO-1 in 
Schwann cells may also enhance neuroprotection.40 Here, bFGF stimulated HO-1 
expression in sciatic nerve cells, as was previously reported in spinal astrocyte culture.31 
We also demonstrated that vein wrapping further stimulated HO-1 expression in sciatic 
nerve tissue. Sciatic nerve contains several cell types, including Schwann cells, 
fibroblasts, macrophages, perineural cells, pericytes, endothelial cells, mast cells and 
some classes of progenitor cells. 41-45 In present study, the mechanism of increase of 
HO-1 expression in response to bFGF in specific cells of sciatic nerve were not 
determined; however, previous findings, taken together with our present results, suggest 
that bFGF derived from veins exerts a neuroprotective effect via the induction of HO-1 
in injured sciatic nerves.  
Vein wrapping improved the withdraw threshold 3 to 5 days after CCI; however, both 
HO-1 mRNA expression level in sciatic nerve and the withdraw threshold level of the 
CCI+VW group decreased almost to almost the same degree as in the CCI group only 
14 days after surgery. Our preliminary study showed that bFGF expression in vein 
gradually decreased after vein wrapping (data not shown). On this basis, we suggest that 
while vein wrapping induced HO-1 expression in the early phase, it may have had 
limited efficacy in the late phase. 
Several limitations of this study warrant mention. First, veins harvested from other rats 
are not autografts. We previously used veins harvested from another rats as a vein 
wrapping model, and therefore used the same model in this study. However, to mimic 
autografts, inbred rats may be more suitable than a closed colony. Second, although we 
found that exogenously added recombinant bFGF stimulated HO-1 expression in sciatic 
nerve cultures, several authors have reported that bFGF exerts neuroprotective effects 
via a reduction in inflammatory cytokine release 46 or nitric oxide-induced cell death. 47 
It remains to be determined whether bFGF induces other pathways which contribute to 
the relief of allodynia following vein wrapping. Finally, we revealed that HO-1 
expression was elevated in the CCI + VW group; however, it remains unclear if the 
elevation of HO-1 levels contributes to the attenuation of allodynia. 
 In conclusion, the present findings suggest that vein-derived bFGF may contribute to 
the therapeutic efficacy of vein wrapping through the induction of HO-1 expression. 
This finding may lead to the development of new therapeutic targets for treating 
neuropathic pain caused by recurrent compressive neuropathy or traumatic peripheral 
nerve injury. 
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 Figure legends 
 
Figure 1. Withdrawal threshold in the sham, CCI, and VW + CCI groups 
Rats in the CCI group displayed mechanical allodynia during the first 14 days after 
surgery. Vein wrapping following CCI significantly reduced allodynia as compared to 
the CCI group from days 3 to 5 after surgery (*, p<0.05). Data are presented as the 
mean ± SE (n=6, each time point).  
 
Figure 2. Representative immunohistochemical staining of bFGF and bFGF mRNA 
expression in the sciatic nerve and veins 
(A,B) bFGF-positive cells (brown) in the veins (A) and sciatic nerve (B) 
counterstained with haematoxylin (blue). (C) bFGF-positive cells in the sciatic nerve 
were observed in the nerve bundle (arrows). bFGF-positive cells were mainly observed 
in the tunica media and adventitia (arrows), and were also detected at lower numbers in 
the tunica intima (arrow heads). Scale bar = 10 µm. bFGF mRNA expression in veins 
was significantly increased in comparison with that in the sciatic nerve (*, p<0.05). 
Data are presented as the mean ± SE (n=5, each group). 
 Figure 3. Effect of bFGF on HO-1 mRNA expression in sciatic nerve cells  
Real-time PCR analysis revealed that the expression of HO-1 mRNA increased two 
fold in sciatic nerve cells in the presence of exogenously added bFGF (1 ng/ml) 
compared to untreated control cells (*, p<0.05). Values are reported as the fold increase 
in mRNA levels compared with untreated cells (0 ng/ml bFGF). Data are presented as 
the mean ± SE (n=4, each group). 
 
Figure 4. Effect of vein wrapping on HO-1 mRNA expression in the sciatic nerve  
Vein wrapping following CCI significantly increased HO-1 mRNA expression in 
comparison with the CCI group from days 3 to 7 after surgery (*, p<0.05). HO-1 mRNA 
expression in the CCI+VW group was most significantly increased on day 5 after 
surgery (**, p<0.01). Data are presented as the mean ± SE (n=5, each time point). 
 
Figure 5. HO-1 protein concentration in the sciatic nerve on day 5 after chronic 
constriction injury  
HO-1 protein concentration was significantly higher in the CCI and CCI+VW groups 
following surgery. The HO-1 protein concentration in the CCI + VW group significantly 
increased as compared with the CCI group (p<0.05). Data are presented as the mean ± 
SE (n=8, each group). 
 
Figure 6. Representative immunohistochemistry staining of S100 and HO-1 in the 
sciatic nerve 
S100 and HO-1-positive cells (brown) in sciatic nerves counterstained with 
haematoxylin (blue) in the CCI (A-C) and CCI + VW (D-F) groups. A-C) Expression of 
S100 (A) and HO-1 (B, C) in the CCI group (n=3). D-F) Expression of S100 (D) and 
HO-1 (E, F) in the CCI + VW group (n=3). 
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Tables  
Table 1. Sequences of the primers used in this study. 
Gene Direction Primer Sequence (5′–3′) Product Size (bp) 
bFGF F TCC AAG CAG AAG AGA GAG GA 205 
R TGC CCA GTT GGT TTC AGT G 
HO-1 F GAG CGA AAC AAG CAG AAC CC 167 
R ACC TCG TGG AGA CGC TTT AC 
GAPDH F TGC CAC TCA GAA GAC TGT GG 129 
R TTCAGCTCTGGGATGACCTT 
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